Phase 1 Trial for DCC-2812 in Metastatic Castration-Resistant Prostate Cancer

/in , , /by

DCC-2812 is a new oral drug designed to fight advanced cancers, especially in the urinary and reproductive systems like kidney, bladder, and prostate cancers. It works by turning on a special stress response inside cancer cells that pushes them past their breaking point, leading to cell death. Cancer cells live in harsh environments with low […]

Read more

Preliminary Data From a Phase 1/2 Trial of PDS01ADC Plus Docetaxel in mCRPC

/in , , , /by

Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC  (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]

Read more

New Phase 3 Trial For BNT324 in Metastatic Castration-Resistant Prostate Cancer

/in , , /by

BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]

Read more

Actinium‑225 NTSR1‑Targeted Radiopharmaceutical SKL35501

/in , , /by

SKL35501 is an emerging radiopharmaceutical therapy that embodies much of what “next‑generation oncology” is supposed to mean: precise targeting, potent cell kill, and a built‑in companion diagnostic strategy. In January 2026, the US FDA cleared SKL35501 and its imaging partner SKL35502 for a phase 1 Investigational New Drug (IND). SKL35501 originated as FL‑091, a small‑molecule […]

Read more

Recent Discovery on tRNA Halves in Prostate Cancer

/in /by

Tiny pieces of genetic material called tRNA halves play a surprising role in fueling prostate cancer growth, according to new research published in PLOS Biology. These molecules form when normal tRNA, short strands of RNA that help build proteins, get split in half inside cells, especially those driven by male hormones like in prostate cancer. […]

Read more

ARREST Trial: Precision Radiation Boosts to Fix 177Lu-PSMA’s 50% Failure Rate

/in , , /by

ARREST trial could change mCRPC treatment by solving 177Lu-PSMA’s biggest limitation: up to 50% of patients get little benefit despite FDA approval and proven survival gains. The simple idea? Add targeted external beam radiation boosts to the tumors that radioligand therapy misses, creating a hybrid approach that could cut skeletal complications dramatically. Current 177Lu-PSMA therapy […]

Read more

Smart Antibody Medicines: How the ALCO5 Platform Could Upgrade Targeted Cancer Therapy

/in , , /by

ALCO5 is a new way of building “smart” cancer drugs that combine an antibody with a powerful medicine in a single, targeted package. The aim is to hit cancer cells much harder while sparing as much healthy tissue as possible, and to do this with drug types that previously could not be used in these […]

Read more

Docetaxel Rechallenge vs Cabazitaxel in mCRPC: VA Cohort Study

/in /by

A retrospective cohort study published January 2, 2026, in JAMA Network Open compared docetaxel rechallenge to cabazitaxel in 669 patients with metastatic castration-resistant prostate cancer treated in the Veterans Affairs healthcare system from 2010 to 2023. All patients had received at least three cycles of initial docetaxel without disease progression and then one intervening systemic […]

Read more